Vergoeding 2015-2019 voor ATC-subgroep L04AA : Selectieve immunosuppressiva
- Raming voor de totale Zvw-populatie
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| L04AA06 Mycofenolzuur (Cellcept ®) | 10.651.700 | 10.999.300 | 11.032.600 | 10.949.500 | 11.718.200 |
| L04AA10 Sirolimus (Rapamune ®) | 1.532.400 | 1.520.200 | 1.454.900 | 1.458.200 | 1.484.900 |
| L04AA13 Leflunomide (Arava ®) | 2.269.500 | 1.995.400 | 1.924.700 | 2.039.200 | 2.327.700 |
| L04AA18 Everolimus (Certican ®) | 3.143.800 | 4.053.400 | 4.252.200 | 4.946.800 | 5.238.700 |
| L04AA27 Fingolimod (Gilenya ®) | 21.522.300 | 22.922.700 | 24.383.400 | 27.139.200 | 27.436.800 |
| L04AA31 Teriflunomide (Aubagio ®) | 4.810.200 | 8.508.200 | 10.978.200 | 12.681.800 | 14.037.300 |
| L04AA40 Cladribine (Mavenclad ®) | . | . | . | 2.280.000 | 4.663.800 |
| Totaal | 43.929.900 | 49.999.200 | 54.026.000 | 61.494.700 | 66.907.400 |